BUFFALO, N.Y., April 25 /PRNewswire-FirstCall/ -- Cleveland BioLabs (CBLI) announces the following Webcast:
What: Cleveland Biolabs Investor Update Call When: April 28, 2010 @ 10:00 AM Eastern Where: http://www.investorcalendar.com/ClientPage.asp?ID=157342 Live over the Internet --Simply log on to the web at the address How: above. Contact: Rachel Levine, 646-284-9439, rlevine@cbiolabs.com
If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=157342 or http://www.investorcalendar.com/
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop a robust pipeline of drugs for multiple medical and defense applications.
CBLI's pipeline includes products from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation, chemotherapy and ischemias (pathologies developed as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer agents.
CBLI's lead drug candidate, CBLB502, is being developed as a countermeasure for Acute Radiation Syndrome and as a supportive care measure to reduce and prevent the occurrence of side effects of radiotherapy or chemotherapy in cancer treatment.
CBLI has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. The company was founded by Andrei Gudkov, Michael Fonstein, and Yakov Kogan in 2003. Cleveland BioLabs is headquartered in Buffalo, NY.
Cleveland BioLabs, Inc.
CONTACT: Rachel Levine, +1-646-284-9439, rlevine@cbiolabs.com
Web Site: http://www.cbiolabs.com/
